{"id":1906,"date":"2019-09-26T18:29:17","date_gmt":"2019-09-26T16:29:17","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1906"},"modified":"2023-07-28T14:19:24","modified_gmt":"2023-07-28T12:19:24","slug":"malalties-de-cap-i-coll","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/malalties-de-cap-i-coll\/","title":{"rendered":"Malalties de cap i coll"},"content":{"rendered":"\n
El Grup de Recerca de Cap i Coll, en la seva l\u00ednia de recerca oncol\u00f2gica, estudia noves dianes terap\u00e8utiques i biomarcadors predictius de resposta a QMT, RT i immunoter\u00e0pia, el paper del virus del papil\u00b7loma hum\u00e0 (HPV) i el maneig diferencial dels tumors HPV+, el tractament trans-oral del C\u00e0ncer de Laringe amb l\u00e0ser CO2 i Cirurgia Rob\u00f2tica, cirurgia reconstructiva i rehabilitaci\u00f3 fonat\u00f2ria dels pacients laringectomitzats.<\/p>\n
Haddad,RI;Harrington,K;Tahara,M;Ferris,RL;Gillison,M;Fayette,J;Daste,A et al, Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651<\/strong>., J. Clin. Oncol., 2022;doi:10.1200\/JCO.22.00332,<\/p>\n Salawu,A;Hernando Calvo,A;Chen,RY;Araujo,DV;Oliva,M;Liu,ZA;Siu,LL, Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials<\/strong>., Eur. J. Cancer, 2022;173167-177, doi:10.1016\/j.ejca.2022.06.045,<\/p>\n Hernando Calvo,A;Salawu,A;Chen,RY;Araujo,DV;Oliva,M;Liu,ZA;Siu,LL, A risk stratification model for toxicities in phase 1 immunotherapy trials<\/strong>., Eur. J. Cancer, 2022;17511-18, doi:10.1016\/j.ejca.2022.08.003,<\/p>\n Arribas,L;Sabat\u00e9 Llobera,A;Domingo,MC;Taberna,M;Sospedra,M;Martin,L;Gonz\u00e1lez Tamp\u00e1n,AR et al, Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards<\/strong>., Clin. Nutr., 2022;41(5):1059-1065, doi:10.1016\/j.clnu.2022.03.016,<\/p>\n Pons Escoda,A;Garcia Ruiz,A;Naval Baudin,P;Grussu,F;Fernandez,JJS;Simo,AC;Sarro,NV et al, Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis<\/strong>., Eur Radiol, 2022;32(6):3705-3715, doi:10.1007\/s00330-021-08498-1,<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II\/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT\/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA<\/strong>. Budget: 236335,84. 2020- . PI: Plana Serrahima, Mar\u00eda.<\/p>\n 21ACL104. A RANDOMIZED, DOUBLE-BLIND PLACEBOCONTROLLED, PHASE 3 STUDY OF DEBIO 1143 IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AND STANDARD FRACTIONATION INTENSITY-MODULATED RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY (TRILYNX)<\/strong>. Budget: 173660,76. 2021- . PI: Oliva Bernal, Marc.<\/p>\n 2022-232-1. A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors<\/strong>. Seagen Inc. Budget: 171306,45. 2022- . PI: Oliva Bernal, Marc.<\/p>\n 20ACL181. ESTUDIO DE FASE II, ABIERTO Y MULTIC\u00c9NTRICO DE AL101 EN PACIENTES CON CARCINOMA ADENOIDE QU\u00cdSTICO (ACC) CON MUTACIONES ACTIVADORAS NOTCH<\/strong>. Budget: 97497. 2020- . PI: Oliva Bernal, Marc.<\/p>\n PSJ22006. MoleculaR profiling and ImmunophEnotyping as preDictors of outcomE in non-metastatic SalIvary Gland carciNomas (REDESIGN)<\/strong>. Grupo Espa\u00f1ol de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Budget: 80000. 2022-2024. PI: Oliva Bernal, Marc.<\/p>\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t Actualment els projectes m\u00e9s rellevants estan dirigits a l’estudi del c\u00e0ncer d’orofaringe, sobretot en pacients HPV positius, \u00a0a la recerca de biomarcadors de pron\u00f2stic i agressivitat de la malaltia per adequar-hi el tractament adient, aix\u00ed com a la recerca d’una signatura gen\u00e8tica \u00a0per a cercar un tractament m\u00e9s personalitzat en pacients amb c\u00e0ncer d’orofaringe.<\/p>\n\t\t\t\t\n Malalties de cap i coll Resum El Grup de Recerca de Cap i Coll, en la seva l\u00ednia de recerca oncol\u00f2gica, estudia noves dianes terap\u00e8utiques i biomarcadors predictius de resposta a QMT, RT i immunoter\u00e0pia, el paper del virus del papil\u00b7loma hum\u00e0 (HPV) i el maneig diferencial dels tumors HPV+, el tractament trans-oral del C\u00e0ncer […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 11:13:55","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1906"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906\/revisions"}],"predecessor-version":[{"id":24085,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906\/revisions\/24085"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n\t\tMa\u00f1os Pujol, Manel\n\t<\/h4>\n
\n\t\t\n\t\tmmanos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n
\n\t\tMa\u00f1os Pujol, Manel\n\t<\/h4>\n
\n\t\t\n\t\tmmanos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tOliva Bernal, Marc \n\t<\/h4>\n
\n\t\t\n\t\tmoliva@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tArribas Hortig\u00fcela, Lorena\n\t<\/h4>\n
\n\t\t\n\t\tlarribas@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\t@OlivaM_Onc\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tCol\u00b7laboradors\/es\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting AES 2019 sobre els Projectes de Recerca en Salut finan\u00e7ats per l’ISCIII<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/03\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa investigadora Purificaci\u00f3n Mu\u00f1oz rep el V premi Mart\u00ed Via<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/11\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl c\u00e0ncer de tu a tu: Pacients, metges, investigadors i activistes de la lluita contra el c\u00e0ncer dialoguen i s’obren a la ciutadania<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t13\/09\/2018\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa p\u00e8rdua d’una prote\u00efna fa ‘saltar’ el tumor al gangli limf\u00e0tic<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t06\/03\/2012\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"